Vicente Gimeno‐Ballester

Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C

Ramón San Miguel, Vicente Gimeno‐Ballester, Antonio Blázquez et al. · Gut · 2014 · 54 citations

Análisis de costes de los sistemas de nutrición parental; bolsa tricompartimental versus individualizada

David Berlana, P. Sabín, Vicente Gimeno‐Ballester et al. · Repositori ObertUDL (University of Lleida) · 2013 · 21 citations · Full text

Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost–effectiveness analysis

J Aguilar-Serra, Vicente Gimeno‐Ballester, Alfonso Pastor-Clerigues et al. · Journal of Comparative Effectiveness Research · 2019 · 19 citations

Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer

Moisés Uriarte-Pinto, Á Escolano Pueyo, Vicente Gimeno‐Ballester et al. · International Journal of Clinical Pharmacy · 2016 · 16 citations

Neoadjuvant Setting, Oncology, Breast Oncology +9

Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain

Cristina Trigo-Vicente, Vicente Gimeno‐Ballester, Raquel Montoiro-Allué et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2017 · 16 citations